Amyloidosis - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 59 pages report, published by Global Markets Direct

Keywords : Amyloidosis Therapeutic Products under Development, Key Players in Amyloidosis Therapeutics, Amyloidosis Pipeline Overview, Amyloidosis Pipeline, Amyloidosis Pipeline Assessment

Report ThumbnailSeptember-2013
Amyloidosis - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Amyloidosis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Amyloidosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyloidosis. Amyloidosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Amyloidosis.
- A review of the Amyloidosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Amyloidosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Amyloidosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Amyloidosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Amyloidosis, H2 2013 7
  • Products under Development for Amyloidosis - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Products under Investigation by Universities/Institutes, H2 2013 10
  • Late Stage Products, H2 2013 11
  • Early Clinical Stage Products, H2 2013 12
  • Discovery and Pre-Clinical Stage Products, H2 2013 13
  • Assessment by Monotherapy Products, H2 2013 21
  • Assessment by Route of Administration, H2 2013 22
  • Assessment by Stage and Route of Administration, H2 2013 23
  • Assessment by Molecule Type, H2 2013 24
  • Assessment by Stage and Molecule Type, H2 2013 25
  • List of Tables
  • Number of Products Under Development for Amyloidosis, H2 2013 7
  • Products under Development for Amyloidosis - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Number of Products under Investigation by Universities/Institutes, H2 2013 10
  • Comparative Analysis by Late Stage Development, H2 2013 11
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 13
  • Products under Development by Companies, H2 2013 14
  • Products under Investigation by Universities/Institutes, H2 2013 15
  • GlaxoSmithKline plc, H2 2013 16
  • Onyx Pharmaceuticals, Inc., H2 2013 17
  • ProteoTech, Inc., H2 2013 18
  • Immune System Therapeutics Ltd., H2 2013 19
  • TheraCarb Inc., H2 2013 20
  • Assessment by Monotherapy Products, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 25
  • Amyloidosis Therapeutics - Drug Profile Updates 38
  • Amyloidosis Therapeutics - Dormant Products 46
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Amyloidosis Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Amyloidosis 7
  • Amyloidosis Therapeutics under Development by Companies 9
  • Amyloidosis Therapeutics under Investigation by Universities/Institutes 10
  • Late Stage Products 11
  • Comparative Analysis 11
  • Early Clinical Stage Products 12
  • Comparative Analysis 12
  • Discovery and Pre-Clinical Stage Products 13
  • Comparative Analysis 13
  • Amyloidosis Therapeutics - Products under Development by Companies 14
  • Amyloidosis Therapeutics - Products under Investigation by Universities/Institutes 15
  • Companies Involved in Amyloidosis Therapeutics Development 16
  • GlaxoSmithKline plc 16
  • Onyx Pharmaceuticals, Inc. 17
  • ProteoTech, Inc. 18
  • Immune System Therapeutics Ltd. 19
  • TheraCarb Inc. 20
  • Amyloidosis - Therapeutics Assessment 21
  • Assessment by Monotherapy Products 21
  • Assessment by Route of Administration 22
  • Assessment by Molecule Type 24
  • Drug Profiles 26
  • MDX-1097 - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • carfilzomib - Drug Profile 27
  • Product Description 27
  • Mechanism of Action 27
  • R&D Progress 27
  • eprodisate disodium - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • Systebryl - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • GSK-2315698 - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • Drug For AA Amyloidosis - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • NPT-005 - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • Peptides For Amyloidoses - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • GSK-2398852 - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • Amyloidosis Therapeutics - Drug Profile Updates 38
  • Amyloidosis Therapeutics - Dormant Products 46
  • Amyloidosis - Product Development Milestones 47
  • Featured News & Press Releases 47
  • Aug 28, 2013: Alnylam and Collaborators Publish Clinical Trial Results with RNAi Therapeutics Targeting Transthyretin for the Treatment of TTR-Mediated Amyloidosis in the New England Journal of Medicine 47
  • Jul 23, 2013: KIACTA Granted Orphan Drug Status in Japan 49
  • Jul 11, 2013: Alnylam Reports Positive Top-Line Results for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin for the Treatment of TTR-Mediated Amyloidosis 49
  • Jun 30, 2013: Alnylam Reports Positive Phase II Data for ALN-TTR02 for the Treatment of TTR-Mediated Amyloidosis 51
  • Apr 23, 2013: Prothena Announces Dosing Of First Patient In Phase I Study Of Therapeutic Antibody For Treatment Of AL Amyloidosis 53
  • Feb 27, 2013: Prothena Achieves Orphan Drug Status In EU For Lead Program NEOD001 53
  • Nov 05, 2012: Millennium To Present Data On MLN9708 At American Society Of Hematology Annual Meeting 54
  • Oct 19, 2012: Millennium Initiates Global TOURMALINE-AL1 Pivotal Phase III Trial Of MLN9708 In Patients With Relapsed Or Refractory Primary Amyloidosis 55
  • May 10, 2012: Alnylam Presents Final Results From Phase I Clinical Trial Of ALN-TTR01 For Treatment Of Transthyretin-Mediated Amyloidosis 55
  • May 10, 2012: Bellus Health Announces Update On Phase III Trial Of KIACTA In AA Amyloidosis At XIII International Symposium On Amyloidosis 57
  • Appendix 58
  • Methodology 58
  • Coverage 58
  • Secondary Research 58
  • Primary Research 58
  • Expert Panel Validation 58
  • Contact Us 59
  • Disclaimer 59

Please select a license type

Share

Related Products

Global Markets DirectAmyloidosis - Pipeline Review, H2 2013Product ThumbnailAmyloidosis - Pipeline Review, H2 2013, Industry ReportProduct #: 113299
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved